pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Cibinqo
drug
save

abrocitinib

Marketedupdated 4mo ago
by $PFE PFIZER INC
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying abrocitinib

  • phase3A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczemarecruitingn=150
  • —Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.recruitingn=150
  • phase2Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)active not recruitingn=78
  • phase2Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVIDactive not recruitingn=46
  • phase3A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczemarecruitingn=500
  • —A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.active not recruitingn=1,128
  • phase3Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitiscompletedn=3,166
  • —A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitisrecruitingn=1,100
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 14, 2027
143 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

  • Jan 14, 2036compositionUS 9035074
  • Jan 14, 2036compositionUS 9035074
  • Jan 14, 2036compositionUS 9035074
  • Feb 19, 2034compositionUS 9545405
  • Feb 19, 2034compositionUS 9545405
  • Feb 19, 2034compositionUS 9545405
  • Feb 19, 2034method-of-use (U-3195)US 9549929
  • Feb 19, 2034method-of-use (U-3195)US 9549929
  • Feb 19, 2034method-of-use (U-3195)US 9549929

FDA exclusivities (6)

  • Jan 14, 2027NCENew Chemical Entity (5y)143d
  • Jan 14, 2027NCENew Chemical Entity (5y)143d
  • Jan 14, 2027NCENew Chemical Entity (5y)143d
  • Feb 9, 2026NPPNew Product (3y)
  • Feb 9, 2026NPPNew Product (3y)
  • Feb 9, 2026NPPNew Product (3y)

News(0)

no news has mentioned this drug yet

brand
Cibinqo
generic
abrocitinib
indication
Atopic Dermatitis (Atopic Eczema)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 11m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?